Exactech, Inc. Cleared By FDA For U.S. Distribution Of Equinoxe(R) Reverse Shoulder

Exactech Inc.
(Nasdaq: EXAC), a developer and producer of bone and joint restoration
products including orthopaedic implants and biologic materials, announced
today that it has received clearance from the U.S. Food and Drug
Administration (FDA) to market the Equinoxe(R) Reverse Shoulder, the latest
component in the company’s shoulder arthroplasty line.

A “reverse” shoulder is designed for patients who have an irreparable
rotator cuff and osteoarthritis. The Equinoxe Reverse Shoulder is
compatible with the Equinoxe primary stem, allowing surgeons to change from
a primary to a reverse without removing the humeral stem.

Exactech CEO Bill Petty said, “With the introduction of our Equinoxe
Reverse Shoulder, we have continued the precedent of innovation that we
established with the Equinoxe primary and fracture shoulder systems. The
shoulder market is rapidly growing and we are pleased that we have a
prosthesis that will help address the clinical challenges that surgeons
have faced thus far with reverse shoulders.”

Lynn Crosby, M.D., a leading shoulder surgeon and member of the design
team, said, “The Equinoxe Reverse Shoulder is an exciting new product that
has been designed to address some of the limitations or challenges inherent
in other reverse shoulder systems. I’ve been pleased to work with an
international team of surgeons who brought a great deal of clinical and
surgical expertise to this product’s development.”

Exactech plans to initiate targeted clinical evaluation of the Equinoxe
Reverse Shoulder in its second quarter with full-scale release targeted for
the second half of 2007. Reverse shoulders have only recently been
introduced in the U.S. market. According to industry sources, approximately
49,000 shoulder replacements were performed in the U.S. in 2006, which is a
12% increase from 2005. Roughly 6% of that increase is attributed to
reverse shoulder replacement.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic
implant devices, related surgical instruments and biologic materials and
services to hospitals and physicians. The company manufactures many of its
orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic
products are used in the restoration of bones and joints that have
deteriorated as a result of injury or diseases such as arthritis. Exactech
markets its products in the United States and Australia, in addition to
more than 25 countries in Europe, Asia and Latin America. Copies of
Exactech’s press releases, SEC filings, current price quotes and other
valuable information for investors may be found at exac and

An investment profile on Exactech may be found at

This release contains various forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, which represent the company’s expectations
or beliefs concerning future events of the company’s financial performance.
These forward-looking statements are further qualified by important factors
that could cause actual results to differ materially from those in the
forward- looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of third party
manufacturers to produce components on a basis which is cost-effective to
the company, market acceptance of the company’s products and the effects of
government regulation. Results actually achieved may differ materially from
expected results included in these statements.

Exactech, Inc.

This entry was posted in Uncategorized. Bookmark the permalink.